Published in FEBS Lett on July 25, 1994
Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut (2000) 1.75
Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol (1997) 1.51
Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver. World J Gastroenterol (2000) 1.05
Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci (2011) 0.85
Evidence for altered hepatic matrix degradation in genetic haemochromatosis. Gut (1998) 0.80
Enhanced migration of tissue inhibitor of metalloproteinase overexpressing hepatoma cells is attributed to gelatinases: relevance to intracellular signaling pathways. World J Gastroenterol (2005) 0.77
The antifibrotic and fibrolytic properties of date fruit extract via modulation of genotoxicity, tissue-inhibitor of metalloproteinases and nuclear factor- kappa B pathway in a rat model of hepatotoxicity. BMC Complement Altern Med (2016) 0.75
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 5.42
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line. Proc Natl Acad Sci U S A (1988) 3.19
Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J Virol (1998) 2.71
Integral and peripheral protein composition of the apical and basolateral membrane domains in MDCK cells. J Membr Biol (1989) 2.65
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 2.30
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol (1994) 2.26
Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem (1996) 2.19
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol (2006) 1.95
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
Structure of an extracellular gp130 cytokine receptor signaling complex. Science (2001) 1.94
The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol (1996) 1.93
IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 1.79
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol (1995) 1.70
TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol (1999) 1.69
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
An evaluation of 2,5-norbornadiene as a reversible inhibitor of ethylene action in deepwater rice. Plant Physiol (1987) 1.60
Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol (2000) 1.55
Abnormal postprandial duodenal chyme transport in patients with long standing insulin dependent diabetes mellitus. Gut (1997) 1.54
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1998) 1.51
Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50
A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem (1996) 1.47
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
[Severe refractory pulmonary hypertension after liver transplantation for hepatitis C liver cirrhosis]. Z Gastroenterol (2006) 1.39
[Premedication for endoscopy]. Dtsch Med Wochenschr (2001) 1.39
[Treatment options for vascular ectasias of the gastric antrum (watermelon stomach)]. Dtsch Med Wochenschr (2001) 1.38
ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol (2001) 1.37
Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 1.32
Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem (2000) 1.32
STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut (2006) 1.30
Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology (1996) 1.26
Development of a human interleukin-6 receptor antagonist. J Biol Chem (1994) 1.25
Current concepts in cholesterol gallstone pathogenesis. Eur J Clin Invest (1991) 1.25
The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw (2000) 1.21
In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol (1998) 1.19
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol (1998) 1.19
Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J Hepatol (1996) 1.19
Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem (1993) 1.18
Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain (2005) 1.15
Multiple intraluminal electrical impedancometry for recording of upper gastrointestinal motility: current results and further implications. Am J Gastroenterol (1999) 1.14
A new technique for endoscopic implantation and explantation of large-bore biliary endoprostheses in patients with non-surgical common bile duct obstruction. Endoscopy (1987) 1.14
Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol (1998) 1.13
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia (1999) 1.12
Postoperative adaptation of the small intestine after total colectomy and J-pouch-anal anastomosis. Dis Colon Rectum (1989) 1.12
Chyme transport patterns in human duodenum, determined by multiple intraluminal impedancometry. Am J Physiol (1995) 1.12
Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock. J Biol Chem (1998) 1.11
Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci (1999) 1.11
Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol (1999) 1.10
Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc Natl Acad Sci U S A (2001) 1.10
Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett (1993) 1.10
Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J (2000) 1.09
Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol (1994) 1.09
Dynamics of esophageal bolus transport in healthy subjects studied using multiple intraluminal impedancometry. Am J Physiol (1997) 1.09
Caroli's syndrome associated with medullary sponge kidney and nephrocalcinosis. Nephrol Dial Transplant (1996) 1.08
Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun (1996) 1.05
Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes. FEBS Lett (1992) 1.05
Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. J Immunol (1991) 1.04
Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. Nucleic Acids Res (1995) 1.04
The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins (1997) 1.04
IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol (2000) 1.03
The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett (1992) 1.03
Purification and characterization of a microsomal bile acid beta-glucosidase from human liver. J Biol Chem (1997) 1.03
Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation (2000) 1.03
TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol (1997) 1.02
Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci U S A (1996) 1.02
Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J (2001) 1.02
Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun (1992) 1.01
The soluble glycoprotein of vesicular stomatitis virus is formed during or shortly after the translation process. J Virol (1986) 1.01
IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem (1999) 1.01
Pathophysiology of the enterohepatic circulation of bile acids. Rev Physiol Biochem Pharmacol (1979) 1.00
Eosinophilic gastroenteritis with severe protein-losing enteropathy: successful treatment with budesonide. Dig Liver Dis (2005) 1.00
The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J Biol Chem (1999) 1.00
The inhibition of interleukin-6-dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130. J Biol Chem (2000) 0.99
Molecular cloning and expression of human bile acid beta-glucosidase. J Biol Chem (2001) 0.99
Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med (1994) 0.99
Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology (2000) 0.99
The mitogen-activated protein (MAP) kinase p38 and its upstream activator MAP kinase kinase 6 are involved in the activation of signal transducer and activator of transcription by hyperosmolarity. J Biol Chem (1999) 0.99
Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur J Biochem (1994) 0.98
Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem (2000) 0.98